In conclusion, increased inflammation, exemplified by elevated IL-1β levels in our study, may act synergistically with drug resistance mechanisms to promote treatment failure and tumor recurrence, highlighting inflammation as a critical cofactor in cancer progression and as a new potential mechanism to target in EGFR mutant-resistant models. The gene discussed is IL1B; the disease is cancer.